Cardiol Therapeutics filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the SEC, establishing a US$150 million shelf for future offerings of common shares, debt, warrants, or units over a 25-month period. No securities are currently being offered, and the filing does not obligate the company to raise capital. The prospectus includes additional disclosure requested by Ontario Securities Commission staff regarding R&D program timelines, cost estimates, expense disaggregation, and the use of proceeds from an October 2024 financing. Cardiol Therapeutics is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease.

Cardiol Therapeutics Inc. announced the publication of its Phase II recurrent pericarditis clinical trial data in the Journal of the American Heart Association. The company operates in the biotechnology industry, focusing on the development of novel therapies for inflammatory and autoimmune diseases.